Abstract
Objective We aimed to evaluate the efficacy and safety of combination bevacizumab/pemetrexed for the treatment of recurrent epithelial ovarian cancer (EOC). Methods Platinum-sensitive or-resistant patients with recurrent or persistent EOC were eligible if they had received up to 2 prior chemotherapy regimens, including a platinum/taxane regimen without prior bevacizumab. Pemetrexed 500 mg/m2 IV and bevacizumab 15 mg/kg IV were administered every 3 weeks. The primary endpoint was 6-month progression-free survival (PFS); other endpoints included toxicities, PFS and overall survival (OS). Results Thirty-four patients received a median of 7 treatment cycles (range, 2-26). Median follow-up was 25.7 months (range, 3.0-47.2). Six month progression-free survival (PFS) was 56% (95% CI: 38-71). The following response rates were documented (%; 95% CI): 0 complete response, 14 partial responses (41%; 25-59), 18 stable disease (53%; 35-70) and 2 progressive disease (6%; 1-20). Median PFS was 7.9 months (95% CI, 4.6-10.9), with a median OS of 25.7 months (95% CI, 15.4-29.8). Twenty-two patients (64.7%) had a platinum-free interval (PFI) of > 6 months prior to enrollment. Grade 3-4 hematologic toxicities included neutropenia (50%), leukopenia (26%), thrombocytopenia (12%) and anemia (9%). Non-hematologic grade 3-4 toxicities included metabolic (29%), constitutional (18%), pain (18%) and gastrointestinal (15%). Two patients developed hematologic malignancies within one year of treatment. Conclusions Combination bevacizumab/pemetrexed is an active option for both platinum-sensitive and-resistant recurrent EOC. Further investigation of cost and novel toxicities associated with this regimen may be warranted.
Original language | English (US) |
---|---|
Pages (from-to) | 535-540 |
Number of pages | 6 |
Journal | Gynecologic Oncology |
Volume | 131 |
Issue number | 3 |
DOIs | |
State | Published - Dec 2013 |
Externally published | Yes |
Keywords
- Bevacizumab
- Pemetrexed
- Phase II
- Recurrent ovarian cancer
ASJC Scopus subject areas
- Oncology
- Obstetrics and Gynecology